[利福平治疗肺结核患者不良反应的研究]

[Study of adverse reactions in pulmonary tuberculosis patients treated with rifampicin].

作者信息

Anastasatu C, Dinulică E, Algeorge G, Cărpinişan L, Varga E, Rudescu D

出版信息

Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol. 1975 Oct-Dec;24(4):213-9.

Abstract

The present study concerns the clinical appraisal of adverse reactions reported in the course of Rifampicin (RMP) treatment, reactions which have given rise to conflicting reports. The lot studied included 243 cases of pulmonary tuberculosis of which 57 were treated according to the 7/7 regime (600 mg RMP), 152 according to the 2/7 regimen (900-1200 mg RMP) and 34 according to the 7/7 followed by the 2/7 regimen. Tolerance to RMP was followed up by a series of adequate tests and close clinical surveillance. Adverse reactions developed in 31.5% to 41.5% of the cases in terms of the treatment scheme. In the intermittent treatment adverse reactions occurred in 17.1% of the cases.

摘要

本研究关注利福平（RMP）治疗过程中报告的不良反应的临床评估，这些反应引发了相互矛盾的报告。所研究的批次包括243例肺结核病例，其中57例按照7/7方案（600毫克RMP）治疗，152例按照2/7方案（900 - 1200毫克RMP）治疗，34例按照7/7方案后接2/7方案治疗。通过一系列适当的检测和密切的临床监测对RMP的耐受性进行跟踪。根据治疗方案，31.5%至41.5%的病例出现了不良反应。在间歇治疗中，17.1%的病例出现了不良反应。